GenMark prices public offering of common stock

NewsGuard 100/100 Score

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a molecular diagnostics company focused on developing and commercializing proprietary eSensor detection technology, announced today the pricing of a public offering of 7,065,600 shares of its common stock at a price to the public of $4.25 per share. GenMark has granted the underwriters an option to purchase up to an additional 1,059,840 shares of common stock to cover over-allotments. The offering is expected to close on June 22, 2011, subject to customary closing conditions.

Canaccord Genuity Inc. is acting as sole book-running manager of the offering, and William Blair & Company, L.L.C. is acting as co-lead manager of the offering. The offering was made pursuant to a registration statement (File No. 333-174524) initially filed with the Securities and Exchange Commission (the "SEC") on May 26, 2011, and that was declared effective on June 16, 2011.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revolutionizing diabetes management with reliable blood glucose monitoring without finger pricking